Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms
#1912
Introduction: Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.
Aim(s): To analyze the impact of ART on development of SREs in NEN patients.
Materials and methods: Retrospective analysis of our NEN database for all patients with BM who presented at our center between 08/2013 and 07/2015. Overall survival (OS) from diagnosis of BM as well as time to SRE (TTSRE) were calculated. In patients experiencing an SRE within 1 month after diagnosis (i.e. before efficacy of ART could be assessed), TTSRE was defined as the time to a subsequent SRE
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Apostolidis L, Jäger D, Winkler E,
Keywords: NEN, bone metastases, antiresorptive treatment, bisphosphonates, denosumab,
To read the full abstract, please log into your ENETS Member account.